{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T12:42:22Z","timestamp":1781613742047,"version":"3.54.5"},"reference-count":36,"publisher":"Elsevier BV","issue":"37","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,25]],"date-time":"2023-07-25T00:00:00Z","timestamp":1690243200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.vaccine.2023.07.052","type":"journal-article","created":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T16:08:54Z","timestamp":1690474134000},"page":"5477-5482","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Long-term immunoprotection after live attenuated measles-mumps-rubella booster vaccination in children with juvenile idiopathic arthritis"],"prefix":"10.1016","volume":"41","author":[{"given":"Mohamad","family":"Hamad Saied","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joeri W.","family":"van Straalen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sytze","family":"de Roock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerrie C.J.","family":"de Joode-Smink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frans M.","family":"Verduyn Lunel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joost F.","family":"Swart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9548-5562","authenticated-orcid":false,"given":"Nico M.","family":"Wulffraat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc H.A.","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.vaccine.2023.07.052_b0005","doi-asserted-by":"crossref","DOI":"10.1038\/s41572-021-00332-8","article-title":"Juvenile idiopathic arthritis","volume":"8","author":"Martini","year":"2022","journal-title":"Nat Rev Dis Primers"},{"issue":"9563","key":"10.1016\/j.vaccine.2023.07.052_b0010","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0140-6736(07)60363-8","article-title":"Juvenile idiopathic arthritis","volume":"369","author":"Ravelli","year":"2007","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.vaccine.2023.07.052_b0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12969-021-00629-8","article-title":"Juvenile idiopathic arthritis: from aetiopathogenesis to therapeutic approaches","volume":"19","author":"Zaripova","year":"2021","journal-title":"Pediatr Rheumatol"},{"issue":"2","key":"10.1016\/j.vaccine.2023.07.052_b0020","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2020-001208","article-title":"Long-term outcomes in patients with polyarticular juvenile idiopathic arthritis receiving adalimumab with or without methotrexate","volume":"6","author":"Lovell","year":"2020","journal-title":"RMD Open"},{"issue":"1","key":"10.1016\/j.vaccine.2023.07.052_b0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13075-020-02326-5","article-title":"Long-term safety and effectiveness of etanercept in JIA: an 18-year experience from the BiKeR registry","volume":"22","author":"Armaroli","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.vaccine.2023.07.052_b0030","doi-asserted-by":"crossref","unstructured":"Hashkes PJ, Uziel Y, Laxer RM. The safety profile of biologic therapies for juvenile idiopathic arthritis. NatRevRheumatol 2010 Oct;6(1759-4804 (Electronic)):561\u201371.","DOI":"10.1038\/nrrheum.2010.142"},{"key":"10.1016\/j.vaccine.2023.07.052_b0035","first-page":"19","volume":"295","author":"Bongartz","year":"2006","journal-title":"Anti-TNF Antibody Therapy in Rheumatoid Arthritis and the Risk"},{"key":"10.1016\/j.vaccine.2023.07.052_b0040","doi-asserted-by":"crossref","unstructured":"Keller M, Pittet LF, Zimmermann P. Immunogenicity and safety of routine vaccines in children and adolescents with rheumatic diseases on immunosuppressive treatment \u2014 a systematic review. European Journal of Pediatrics, vol. 181. Springer Berlin Heidelberg; 2022. p. 1329\u201362.","DOI":"10.1007\/s00431-021-04283-w"},{"issue":"1","key":"10.1016\/j.vaccine.2023.07.052_b0045","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-020-02167-2","article-title":"Opportunistic infections in immunosuppressed patients with juvenile idiopathic arthritis: analysis by the pharmachild safety adjudication committee","volume":"22","author":"Giancane","year":"2020","journal-title":"Arthritis Res Ther"},{"issue":"21","key":"10.1016\/j.vaccine.2023.07.052_b0050","doi-asserted-by":"crossref","first-page":"2818","DOI":"10.1016\/j.vaccine.2017.04.015","article-title":"Varicella vaccination elicits a humoral and cellular response in children with rheumatic diseases using immune suppressive treatment","volume":"35","author":"Groot","year":"2017","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.vaccine.2023.07.052_b0055","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1136\/ard.2006.063586","article-title":"Safety of measles, mumps and rubella vaccination in juvenile idiopathic arthritis","volume":"66","author":"Heijstek","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2023.07.052_b0060","first-page":"2524","article-title":"Burden of comorbid conditions in children and young people with juvenile idiopathic arthritis: a collaborative analysis of 3 JIA registries","volume":"61","author":"Kearsley-Fleet","year":"2022","journal-title":"Rheumatol (United Kingdom)"},{"issue":"23","key":"10.1016\/j.vaccine.2023.07.052_b0065","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1001\/jama.2013.6768","article-title":"Effects of the live attenuated measles-mumps-rubella booster vaccination on disease activity in patients with juvenile idiopathic arthritis: a randomized trial","volume":"309","author":"Heijstek","year":"2013","journal-title":"JAMA \u2013 J Am Med Assoc"},{"key":"10.1016\/j.vaccine.2023.07.052_b0070","article-title":"EULAR\/PRES recommendations for vaccination of paediatric patients with autoimmune inflammatory rheumatic diseases: update 2021","author":"Jansen","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.vaccine.2023.07.052_b0075","unstructured":"Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International league of associations for rheumatology classification of juvenile idiopathic arthritis: second revision, edmonton, 2001. Vol. 31, Journal of Rheumatology. Division of Rheumatology, Department of Pediatrics, University of British Columbia, Vancouver, BC, Canada; 2004. p. 390\u20132."},{"key":"10.1016\/j.vaccine.2023.07.052_b0080","unstructured":"Swart J, Giancane G, Horneff G, Magnusson B, Hofer M, Alexeeva E, et al. Pharmacovigilance in juvenile idiopathic arthritis patients treated with biologic or synthetic drugs: combined data of more than 15,000 patients from Pharmachild and national registries. 2018;1\u201311."},{"key":"10.1016\/j.vaccine.2023.07.052_b0085","unstructured":"R\u00fcmke HC, Visser HKA. Vaccinaties op de kinderleeftijd anno 2004. I. Effectiviteit en acceptatie van het Rijksvaccinatieprogramma. Ned Tijdschr Geneeskd. 2004;148(8):356\u201363."},{"key":"10.1016\/j.vaccine.2023.07.052_b0090","doi-asserted-by":"crossref","unstructured":"Plotkin SA. Correlates of protection induced by vaccination. Vol. 17, Clinical and Vaccine Immunology. Am Soc Microbiol; 2010. p. 1055\u201365.","DOI":"10.1128\/CVI.00131-10"},{"issue":"6","key":"10.1016\/j.vaccine.2023.07.052_b0095","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1136\/annrheumdis-2011-200637","article-title":"Differences in persistence of measles, mumps, rubella, diphtheriaand tetanus antibodies between children with rheumatic disease and healthy controls: a retrospective cross-sectional study","volume":"71","author":"Heijstek","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.vaccine.2023.07.052_b0100","doi-asserted-by":"crossref","unstructured":"Borte S, Liebert UG, Borte M, Sack U. Efficacy of measles, mumps and rubella revaccination in children with juvenile idiopathic arthritis treated with methotrexate and etanercept. Rheumatology (Oxford) [Internet]. 2009 Feb [cited 2011 Nov 16];48(2):144\u20138. <http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/19074187>.","DOI":"10.1093\/rheumatology\/ken436"},{"issue":"10","key":"10.1016\/j.vaccine.2023.07.052_b0105","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1016\/j.vaccine.2016.01.027","article-title":"Diverse effects on vaccine-specific serum IgG titres and memory B cells upon methotrexate and anti-TNF-\u03b1 therapy in children with rheumatic diseases: a cross-sectional study","volume":"34","author":"Ingelman-Sundberg","year":"2016","journal-title":"Vaccine"},{"issue":"9","key":"10.1016\/j.vaccine.2023.07.052_b0110","first-page":"1686","article-title":"Long-term preservation of measles and rubella specific-IgG antibodies in children with enthesitis related arthritis on anti-TNF\u03b1 treatment: a prospective controlled study","volume":"58","author":"Maritsi","year":"2019","journal-title":"Rheumatol (United Kingdom)"},{"issue":"7","key":"10.1016\/j.vaccine.2023.07.052_b0115","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1177\/0961203310397409","article-title":"Vaccine antibodies and T- and B-cell interaction in juvenile systemic lupus erythematosus","volume":"20","author":"Miyamoto","year":"2011","journal-title":"Lupus"},{"key":"10.1016\/j.vaccine.2023.07.052_b0120","article-title":"Safety of Measles-Mumps-Rubella booster vaccination in patients with juvenile idiopathic arthritis: a long-term follow-up study","author":"Hamad Saied","year":"2023","journal-title":"Vaccine"},{"issue":"9","key":"10.1016\/j.vaccine.2023.07.052_b0125","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1016\/j.vaccine.2020.01.037","article-title":"Live attenuated MMR\/V booster vaccines in children with rheumatic diseases on immunosuppressive therapy are safe: multicenter, retrospective data collection","volume":"38","author":"Uziel","year":"2020","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.vaccine.2023.07.052_b0130","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1080\/14760584.2021.1875825","article-title":"Immune response and safety of viral vaccines in children with autoimmune diseases on immune modulatory drug therapy","volume":"19","author":"Tse","year":"2020","journal-title":"Expert Rev Vaccines"},{"issue":"2","key":"10.1016\/j.vaccine.2023.07.052_b0135","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.autrev.2011.08.010","article-title":"Vaccination in paediatric patients with auto-immune rheumatic diseases: a systemic literature review for the European League against Rheumatism evidence-based recommendations","volume":"11","author":"Heijstek","year":"2011","journal-title":"Autoimmun Rev"},{"issue":"9","key":"10.1016\/j.vaccine.2023.07.052_b0140","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1097\/INF.0000000000001241","article-title":"Safety and immunogenicity of M-M-RII (Combination Measles-Mumps-Rubella Vaccine) in clinical trials of healthy children conducted between 1988 and 2009","volume":"35","author":"Kuter","year":"2016","journal-title":"Pediatr Infect Dis J"},{"issue":"37","key":"10.1016\/j.vaccine.2023.07.052_b0145","doi-asserted-by":"crossref","first-page":"4703","DOI":"10.1016\/j.vaccine.2014.06.088","article-title":"Measles and mumps outbreaks in the United States: think globally, vaccinate locally","volume":"32","author":"Whitaker","year":"2014","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2023.07.052_b0150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12879-020-04956-1","article-title":"Measles and mumps outbreaks in Lebanon: trends and links","volume":"20","author":"El Zarif","year":"2020","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2023.07.052_b0155","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1017\/S0950268821002028","article-title":"Mumps outbreak among fully vaccinated school-Age children and young adults, Portugal 2019\/2020","volume":"149","author":"Perez Duque","year":"2021","journal-title":"Epidemiol Infect"},{"issue":"1","key":"10.1016\/j.vaccine.2023.07.052_b0160","first-page":"1","article-title":"Seroprevalence to measles virus after vaccination or natural infection in an adult population","volume":"8","author":"Anichini","year":"2020","journal-title":"Italy Vaccines (Basel)"},{"issue":"6","key":"10.1016\/j.vaccine.2023.07.052_b0165","first-page":"902","article-title":"A third dose of measles-mumps-rubella vaccine to improve immunity against mumps in young adults","volume":"221","author":"Kaaijk","year":"2020","journal-title":"J Infect Dis"},{"issue":"7","key":"10.1016\/j.vaccine.2023.07.052_b0170","doi-asserted-by":"crossref","first-page":"e1546","DOI":"10.1093\/cid\/ciaa1090","article-title":"Adverse events among young adults following a third dose of measles-mumps-rubella vaccine","volume":"73","author":"Marin","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2023.07.052_b0175","doi-asserted-by":"crossref","first-page":"357","DOI":"10.24953\/turkjped.2017.04.001","article-title":"Current information about vaccination practice in pediatric rheumatic diseases and recommendations for future applications","volume":"59","author":"A\u00e7ar\u0131","year":"2017","journal-title":"Turk J Pediatr"},{"issue":"7","key":"10.1016\/j.vaccine.2023.07.052_b0180","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1007\/s00431-021-03997-1","article-title":"Vaccination of immune compromised children\u2014an overview for physicians","volume":"180","author":"Pittet","year":"2021","journal-title":"Eur J Pediatr"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23008836?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23008836?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:28:58Z","timestamp":1759404538000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X23008836"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":36,"journal-issue":{"issue":"37","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S0264410X23008836"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.07.052","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term immunoprotection after live attenuated measles-mumps-rubella booster vaccination in children with juvenile idiopathic arthritis","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.07.052","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}